Event Participants
Executives
5
Mahesh Babani, Narayan S. Iyer, R.S. Rajan, Sanjeev Patil, Ashwini Shah
Analysts
10
Aniket (CRK Research), Krish Talot (WeGrowth AIF), Manisha Dalal (Universal Capital), Nathan James (Moore PMS), Nikhil Jadhav (Purnartha Investment Advisors), Nirav Gandhi (Sunidhi Securities), Rajesh Mishra (Liberty Trading), Sahil Goyal (Equinox Capital Ventures), Suraj Shinde (YES Securities), Vivek Rakholiya (FiCOM Family Office)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹666 crore | +19.22% YoY; driven by volume growth, price increases, and improved product mix across domestic and international markets |
| Total Income (Consolidated) | ₹681.42 crore | +20.01% YoY; includes other income |
| EBITDA | ₹167.47 crore | +18.73% YoY; supported by operational efficiencies, lower manufacturing and administrative expenses |
| EBITDA Margin | 24.58% | ~25% sustained across last 9 quarters; management expects 20%+ going forward |
| Gross Margin | 44.2% | Down ~680 bps YoY from 51% in Q1 FY26; unfavorable RM mix versus low-cost raw material advantage in prior year; RMC expected to normalize at 52–54% of sales |
| PAT | ₹83.2 crore | vs ₹61.46 crore in Q1 FY26 (+35.4% YoY); aided by lower depreciation and interest impact |
| Working Capital Cycle | 108 days | Improved from 141 days in Q1 FY26; better inventory and receivables management |
| Net Debt | ₹865 crore | Net of cash and mutual funds, as of June 2026 |
| Net Debt / EBITDA | 1.29x | Reflects financial flexibility while supporting growth investments |
| Net Debt / Equity | 0.57x | Prudent capital structure maintained |
| ROE | 21.7% | Quarterly performance |
| ROCE | 22.72% | Quarterly performance |
| Capacity & Utilization | 48,000 MT, ~90% utilized | Operating near full utilization; phase I expansion to 54,000 MT expected to commercialize within ~15 days (by September 2026); phase II to 66,000 MT by September 2027 |
Geographic & Segment Commentary
Fragrance & Flavor (Core Aroma Chemicals): Demand remained healthy across the fragrance and flavor value chain despite global headwinds. Growth was supported by supply chain diversification, dependable sourcing, premiumization, and innovation across end-use categories. Revenue grew 19.22% YoY with ~90% capacity utilization across 75+ products.
Domestic & International Markets: Both markets contributed to growth during the quarter, with global customers increasingly prioritizing supply chain diversification and India as an alternate sourcing destination. Longstanding customer relationships continue to drive existing product growth and new business opportunities.
Specialty Product Pipeline: Product development progressing well on high-value specialty molecules — maltol, ethyl maltol, ethylene brassylate, Musk T, and cyclopentanone. The long-term roadmap envisages introduction of 10 advanced specialty products as part of phase II and phase III expansion.
Pine Chemistry & Backward Integration: Backward integration into pine chemistry and a diversified global raw material procurement network (CST and GTO) provide sourcing flexibility and supply resilience. Camphor, made primarily via the CST route, represents only ~4–6% of total revenue and is not a strategically significant product.
Prigiv JV (Givaudan Partnership): JV achieved profitability in Q4 FY26 and continued scaling in Q1 FY27 with revenue of ~₹18 crore and EBITDA margins of 14–15%. The JV manufactures 42 products exclusively for Givaudan; an additional ₹50 crore equity infusion supports the next phase of capacity expansion.
Proposed Merger (Privi Fine Sciences & Privi Biotechnologies): Merger scheme filed with NCLT post receipt of no-objection observation letters from both stock exchanges — an important milestone. Post-merger, Privi Fine Sciences adds ~6,000 MT of capacity to the consolidated portfolio.
Company-Specific & Strategic Commentary
Capacity Expansion Roadmap: Phase I expansion (48,000 → 54,000 MT) is progressing and expected to commercialize shortly (~September 2026). Phase II expansion to 66,000 MT is on track for September 2027 completion. Total CapEx outlay of ₹850–900 crore across the current and next two years, split broadly into ~₹300 crore existing product expansion, ~₹300 crore new products, and ~₹300 crore new specialty molecules.
New Product Development (Furfural Platform): Privi is building the world's only fully backward-integrated corn cob → furfural → maltol/ethyl maltol/cyclopentanone manufacturing chain, with a superior proprietary furfural technology. This vertical alone is expected to add ₹1,000+ crore in revenue. New product plants targeted for mechanical completion by mid-FY28, with revenue contribution from H2 FY28.
Merger & Consolidation: The merger of Privi Speciality Chemicals, Privi Fine Sciences, and Privi Biotechnologies is intended to simplify group structure, enhance operational synergies, and improve scalability. NCLT application filed; merger expected to complete in FY27.
Biotechnology & Bio-based Platform: A demonstration plant (2 tons biomass/day) is being set up in Navi Mumbai to validate conversion of biomass into value-added products. This is a post-₹5,000 crore roadmap initiative — the next 2–3 years will focus on learning and scale-up. Multiple patents being filed.
Continuous Flow Chemistry: Distillation is largely continuous across operations; continuous manufacturing is being deployed for new large-scale molecules (e.g., maltol) to improve process efficiency and cost competitiveness.
Strategic Alliances: Management prefers strategic alliances over new joint ventures (to avoid customer conflicts); 2 strategic alliances are currently underway, with details to be announced at an appropriate time.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | ~20% CAGR minimum; ₹5,000 crore revenue in 3–4 years | Management reaffirmed vision of ~2x growth from ~₹2,500 crore current run-rate; phase I (September 2026) and phase II (September 2027) capacity additions underpin this trajectory |
| EBITDA | ₹1,000+ crore in 3–4 years; margins sustaining 20%+ | Q1 FY27 margin of 24.58%; margin resilience driven by operational efficiencies, improved product mix, and scale benefits from new capacities |
| Capacity | 54,000 MT by September 2026; 66,000 MT by September 2027 | Phase I commissioning imminent (~15 days); phase II timeline clarified as September 2027 (annual report earlier indicated June 2027) |
| New Products | Mechanical completion by mid-FY28; revenue from H2 FY28 | Furfural-based molecules (maltol, ethyl maltol, cyclopentanone) and Musk T; targeted at ~25% of global capacity opportunity for key molecules |
| Merger | Completion in FY27 | NCLT application filed; awaited approval; adds ~6,000 MT capacity from Privi Fine Sciences |
| CapEx | ₹850–900 crore over current + next 2 years | Funded primarily through internal accruals; selective debt at competitive rates; debt-to-EBITDA and debt-to-equity to remain well below thresholds |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | Alpha-pinene prices are at historic highs (+70–80% over last 5 months per analyst); CST and GTO are imported with cyclical price swings. Management mitigates via back-to-back customer contracts on CST and pass-through pricing; RMC expected to stay in 52–54% band. |
| Geopolitical Disruptions | Iran war and Red Sea/Houthi tensions have not materially impacted raw material costs or freight to date; crude-based raw materials are only ~15–18% of total purchases. Management noted continued monitoring but no current margin impact. |
| Chinese Competitive Dominance | Over 95% of global maltol/ethyl maltol production is China-based; Privi's competitive edge rests on being the only fully backward-integrated producer from corn cob, with GMP-certified plants and India+1 sourcing demand. |
| Project Execution Delays | Phase I capacity expansion slipped from June 2026 to September 2026 (monsoon-related). Phase II and III timelines carry execution risk; management maintains guidance unchanged. |
| Camphor Market Oversupply | Significant new camphor manufacturing capacity in India has created demand-supply mismatch; impact is limited as camphor is only ~4–6% of revenue and CST-route based with no strategic importance. |
| Regulatory / Merger Approvals | Merger completion depends on NCLT approval timeline; management expects completion within FY27 but exact timing carries regulatory uncertainty. |
| Demand Environment | Management noted "subdued market" conditions despite strong reported growth; sustainability of premiumization and supply chain diversification trends is key to maintaining volume growth. |
Q&A Highlights
Gross Margin Compression & Raw Material Costs
- Question: Gross margin declined ~650 bps YoY to 44.2% despite 20% revenue growth — what drove this, and will it recover during FY27? (Vivek Rakholiya)
- Answer: Last year benefited from low-cost raw materials and favorable selling prices in calendar year 2025; RMC as a percentage of sales is expected to remain in the 52–54% range. RM mix fluctuates due to global sourcing of CST/GTO across different cycles. Savings in manufacturing and administrative expenses, plus lower depreciation and interest, have protected EBITDA-to-PAT conversion. (Narayan S. Iyer, Sanjeev Patil)
Capacity Expansion Timeline & Guidance Reaffirmation
- Question: Is phase II completion June 2027 or September 2027, and would guidance be revised given phase I delays? (Vivek Rakholiya)
- Answer: No change in guidance — the ₹5,000 crore revenue / ₹1,000+ crore EBITDA vision stands. Phase I (48,000 → 54,000 MT) will commercialize in about 15 days (September 2026). Phase II (54,000 → 66,000 MT) is confirmed for September 2027. Management guided to a minimum 20% CAGR with similar EBITDA margins. (Mahesh Babani, Narayan S. Iyer)
Long-Term Revenue / EBITDA Vision
- Question: Would you revise overall FY27 guidance? (Vivek Rakholiya, follow-up)
- Answer: Chairman emphasized: "What last year's number multiply by 20%, again multiply by 20%, that will be the minimum achieving that target." Management is confident of maintaining 20%+ CAGR with EBITDA margins at current levels. (Mahesh Babani)
Prigiv JV Performance & Contribution
- Question: What was Prigiv's Q1 revenue and EBITDA contribution? (Nirav Gandhi)
- Answer: Prigiv generated ~₹18 crore revenue with EBITDA margins of 14–15% in Q1 FY27. The JV achieved profitability in Q4 FY26 and continues to scale; an additional ₹50 crore equity infusion is planned for the next phase of expansion. (Narayan S. Iyer)
Alpha-Pinene Prices & Pass-Through
- Question: Alpha-pinene prices have risen 70–80% in five months — how have you benefited, and what's the outlook? (Nirav Gandhi)
- Answer: CST procurement is done through back-to-back contracts with customers, which protects margins; alpha-pinene from GTO is at historic highs but costs are being passed on to customers. Price direction is unpredictable. (Sanjeev Patil)
Merger Progress & Post-Merger Capacity
- Question: What is the status of the Privi Fine Sciences merger, and what capacity will it add? (Nirav Gandhi; Krish Talot)
- Answer: The scheme has been filed with NCLT after receiving no-objection observation letters from both stock exchanges — completion expected this financial year. Post-merger, ~6,000 MT of capacity will be added to the consolidated portfolio. Privi Fine Sciences currently has no backward integration requirement given its different chemistry and available raw materials. (Narayan S. Iyer, R.S. Rajan)
Maltol Opportunity & Market Positioning
- Question: What is the market opportunity for maltol and Musk T, and who are the target customers? (Nathan James)
- Answer: Over 95% of maltol/ethyl maltol is manufactured in China; India imports significant quantities (especially ethyl maltol for pharma). Privi's plants will be GMP-certified and the company will be the only fully backward-integrated producer globally, from corn cob to maltol — a substantial manufacturing cost advantage. The company targets ~25% of global capacity for key molecules and expects existing customer relationships to drive rapid revenue scale-up. (Sanjeev Patil)
CapEx Funding & Quantum
- Question: What is the total CapEx and the debt/internal accrual split for phase II and III? (Aniket, CRK Research; Suraj Shinde)
- Answer: Total CapEx is ~₹850–900 crore over the current and next two years — ~₹300 crore existing product expansion, ~₹300 crore new products (furfural/maltol), and ~₹300 crore new specialty molecules. Funding will be primarily through internal accruals, with selective borrowing at competitive rates; debt-to-EBITDA and debt-to-equity ratios will remain well below thresholds. (Narayan S. Iyer, Sanjeev Patil)
Biomass Pilot Plant & Next-Gen Technology
- Question: What operational metrics will determine commercial scale-up of the bio-based pilot plant, and what ROCE is targeted? (Vivek Rakholiya)
- Answer: A demonstration plant handling 2 tons of biomass per day is being set up in Navi Mumbai (vs. current few hundred kg per fortnight). After commissioning (~12–15 months), it will run for about a year to study manufacturing nuances before large-scale investment. This is outside the ₹5,000 crore roadmap and will contribute to growth beyond it; multiple patents are being filed. (Sanjeev Patil, Mahesh Babani)
Geopolitical Impact (Red Sea / Iran)
- Question: Are freight costs rising due to Red Sea/Houthi and Iran-war-related disruptions? (Nikhil Jadhav; Rajesh Mishra)
- Answer: No material impact to date — the company has been navigating Red Sea disruptions for years, and crude-based raw materials are only 15–18% of total purchases. Freight and input costs remain manageable and are being absorbed without margin deterioration. (R.S. Rajan, Narayan S. Iyer)
Key Takeaway
Privi Speciality Chemicals delivered a strong Q1 FY27 opening — revenue of ₹666 crore (+19.2% YoY), EBITDA of ₹167.47 crore (24.58% margin), and PAT of ₹83.2 crore (+35.4% YoY) — with working capital improved to 108 days from 141 days and net debt-to-EBITDA at a comfortable 1.29x. Growth was driven by volume, pricing, and product mix across fragrance and flavor markets, supported by supply chain diversification tailwinds and ~90% capacity utilization. Strategically, management is executing phase I capacity expansion to 54,000 MT (September 2026), phase II to 66,000 MT (September 2027), and a ~₹850–900 crore CapEx program anchored on the furfural-to-maltol platform and 10 new specialty molecules, while the Prigiv JV scales with renewed equity and the NCLT merger filing advances. The ₹5,000 crore revenue / ₹1,000+ crore EBITDA vision over 3–4 years at 20%+ margins was reaffirmed with a minimum 20% CAGR. Key watch points remain alpha-pinene at historic highs, raw material cost normalization toward the 52–54% RMC band, execution timelines for phase II/III projects, and geopolitical disruptions to freight and input supply.